36 /100
MEDIUM RISK
Score updated Jul 13, 2026

AARD — Aardvark Therapeutics, Inc. Dilution Risk Tracker

Track AARD dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track AARD — Get alerts when the score changes →

As of July 13, 2026, Aardvark Therapeutics, Inc. (AARD) has a DilutionWatch DilutionScore of 36/100, rated MEDIUM dilution risk. Aardvark Therapeutics, Inc. has a market capitalization of $89.67M, 21.82M shares outstanding, 80 institutional holders tracked. Key dilution vectors include approximately 20 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
30
💰 Cash Runway
25
📊 Float Risk
40
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for AARD.
🔔 Track AARD — Get forecast alerts →

💹 Market Data

Market Cap$89.67M
Shares Outstanding21.82M
Float10.91M
Cash$91.20M
Debt$336.0K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↓ 8.5% shares (2026Q1 vs prior)
80 institutional holders · 11.14M shares
#1 Decheng Capital LLC 3.92M shares
#2 CITADEL ADVISORS LLC 1.30M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 1.11M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest528.3K
Days to Cover1.7
% of Float4.8%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2025
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for AARD Shareholders

Aardvark Therapeutics, Inc. (AARD) has a DilutionScore of 36/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for AARD shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for AARD in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for AARD alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track AARD Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking AARD — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for AARD
📊 AARD FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 AARD Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.